I'm sorry that's simply not true. It's certainly a tough hill to climb and there's certainly no guarantee of success but gen type 1 patients are included in their phase 3 trials.
But really that's beside the point, what I'm try to convey even with a superior product the current Vertex team would not win the race. And anyone hoping this group will expedite these trials should take a long look at the continuing delays in the VX-661 trials.